The objective of our study was to determine the effect of adding r-metHuSCF to Filgrastim and cyclophosphamide for mobilization of peripheral blood progenitor cells (PBPC), on collection of CD34 + cells and engraftment after autologous stem cell transplant. Twenty-three patients with previously treated stage II-IV breast cancer received cyclophosphamide (3 g/m 2 ), Filgrastim 5 g/kg daily and r-metHuSCF 20 g/kg daily. Two PBPC collections were performed on consecutive days starting the day the WBC count was above 7.5 × 10 3 /l. Collection was performed between days +9 and +12 and the median number of CD34 + cells collected was 9.9 × 10 6 /kg (1.1-53.1) and 6.6 × 10 6 /kg (1.4-33.8) for the first and second apheresis, respectively. Despite being previously treated patients, the target CD34 + cell dose required for SCT was obtained in all patients. SCT was associated with rapid neutrophil and platelet engraftment and a highly significant correlation was observed between the number of CD34 + cells infused and engraftment. Treatment with SCF plus filgrastim was well tolerated, with mild to moderate local skin rash being the most frequently reported adverse event. In conclusion, addition of r-metHuSCF induces mobilization of a large number of CD34 + cells which results in shortening of time to engraftment and hospitalization.
Introduction
Mobilized peripheral blood progenitor cells (PBPC) have substituted bone marrow (BM) progenitors for autologous transplantation. [1] [2] [3] Different growth factors have been used to induce mobilization of PBPC including granulocyte colonystimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). 3, 4 Although the use of growth factors makes it possible to collect PBPC for transplantation in most patients, there is a small number of cases in whom enough progenitors to perform an autologous transplant cannot be obtained. The amount of chemotherapy and/or radiotherapy previously received has been associated with poor mobilization and collection of PBPC. 5, 6 Other growth factors have demonstrated a mild to moderate capacity of inducing mobilization when administered alone, but a potent synergistic effect in combination with G-CSF as is the case for the Flt-3 ligand and stem cell factor (SCF, also known as c-kit ligand or Steel factor). 7, 8 SCF is a hematopoietic growth factor that regulates hematopoietic cell proliferation. In vivo, r-metHuSCF has been used in association with G-CSF to induce mobilization of PBPC for autologous trans-plantation 9, 10 and there are several randomized studies indicating that the combination of both cytokines mobilizes significantly more CD34
+ cells than G-CSF alone. [11] [12] [13] [14] However, it is also clear from these studies that the use of r-metHuSCF is not devoid of toxicity. Although there is experience with the use of G-CSF and r-metHuSCF for mobilization of PBPC, the use of both growth factors in combination with chemotherapy is scant. 11, 13 In the current study we have analyzed the effect of adding r-metHuSCF to G-CSF and cyclophosphamide for mobilization of PBPC in a group of patients with breast cancer that had previously been treated with at least six courses of chemotherapy. We have examined the kinetics of mobilization after chemotherapy and growth factors and the potential benefit of harvesting and infusing large numbers of CD34 + cells on short-term engraftment.
Patients and methods

Patient eligibility
Patients between 18 and 65 years of age with histologically proven high risk breast cancer (stage II and more than four lymph nodes affected or stage III locally advanced breast cancer) or metastatic disease without bone marrow involvement were eligible for the clinical trial. Other eligibility criteria included ECOG performance status 0-2 and evidence of normal liver, renal, respiratory and cardiac function. All patients were to have received at least six courses of prior standard chemotherapy with at least 4 weeks from the last day of chemotherapy.
Patients were excluded if they had received prior high-dose chemotherapy with stem cell support, had documented brain metastases, another malignancy within the previous 5 years, a history of asthma, angioedema or recurrent urticaria or allergies to insect venom. Patients who required concurrent therapy with ␤ adrenergic blocking agents were also excluded from the study. The study protocol was approved by each Independent Ethics Committee and written informed consent was obtained for each patient.
Study design
An overview of patients treatment is shown in Figure 1 .
Mobilization and collection of PBPC:
Consecutive eligible patients received cyclophosphamide at a dose of 3 g/m 2 on day +1. Filgrastim 5 g/kg per day and r-metHuSCF 20 g/kg per day subcutaneously were initiated 24 h after cyclophosphamide and continued until the day of the last leukapheresis. All patients received prophylaxis against mast-cell mediated reactions due to r-metHuSCF with cetirizine 10 mg daily, ranitidine 300 mg daily and two puffs of albuterol daily 30-60 min before injection of r-metHuSCF. The total WBC count and CD34 + cell count were analyzed in peripheral blood on days +7, +8, +9, +10, +11 and +12 after mobilization and in the apheresis samples. Leukapheresis was started on the day the WBC was equal to or greater than 7.5 × 10 9 /l. The target cell dose was 2 × 10 6 CD34 + cells/kg and at least two leukaphereses were performed on 2 consecutive days using a blood cell separator (Fenwal CS-3000 plus; Baxter, Healthcare Corporation, Deerfield, IL, USA) using ACD-A as anticoagulant (9:1). The flow rate was 55-65 ml/min and a total of 2-3 blood volumes were processed over 4 h. The apheresis product was cryopreserved and stored in liquid nitrogen until used.
High dose chemotherapy and stem cell transplant:
Within 2 weeks of completing the last apheresis, patients were to start high-dose chemotherapy with cyclophosphamide 1500 mg/m Filgrastim was started on day 0 (30 min after infusion of PBPC) subcutaneously at a dose of 5 g/kg/day until the ANC was Ͼ0.5 × 10 9 /l for 3 consecutive days or 1.0 × 10 9 /l for 1 day or for a maximum of 28 days. Antibiotics, blood products and intravenous fluids were administered as clinically required. Patients were discharged from the hospital when the ANC was maintained above 1.0 × 10 9 /l without filgrastim, and there was no need for antibiotics (no evidence of infection) and oral intake had been resumed. After discharge, patients were followed as outpatients as indicated by their clinical condition. Engraftment and status of the underlying disease were monitored 2 months after transplant.
Sample preparation, flow cytometry data acquisition and analysis were performed as described by Gratama et al 15 and previously published. 16 Toxicity during mobilization and after PBPC transplant was assessed according to the WHO scale.
Statistical analysis
For each variable the mean value, standard deviation and the 95% confidence interval as well as the median value and range were calculated using the SPSS software program (SPSS 6.1.2 Inc, Chicago, IL, USA). The Kaplan-Meier method was used to estimate the time to an event. Pearson's correlation was used to assess the relationship between the number of CD34
+ cells infused/kg of bodyweight and both clinical and biological variables.
Results
Patient characteristics
Between April 1999 and February 2000 a total of 23 women with high risk or metastatic breast cancer were included in the study. Baseline characteristics and demographics for these patients are shown in Table 1 .
Mobilization and collection
The number of WBC and CD34
+ cells in peripheral blood increased from day +7 to day +12 with maximum values on day +12 (mean WBC 46.4 ± 22.78 × 10 9 /l and mean CD34 + cells 514 ± 562/l) ( Figure 2 ). The median number of days required to obtain a WBC count over 7.5 × 10 9 /l was 11 (range 9-12) and in only one patient was apheresis started on day +12. Enough CD34 + cells for transplantation were harvested in all patients after two aphereses. In fact, more than 2 × 10 6
CD34
+ cells/kg body weight were collected after the first aph- + cells per kg of body weight collected after the first or second apheresis were 13.2 ± 13.6 and 11.3 ± 10.3, respectively. We could not find any correlation between the number of CD34 + cells harvested and age, number of previous cycles of chemotherapy or the use of radiotherapy. As we have previously published in detail 16 
Transplantation and engraftment
After high-dose chemotherapy and infusion of PBPC, 22 patients showed platelet and neutrophil engraftment. One patient died from pneumonia on day +8 and could not be evaluated for engraftment. Clinically significant parameters of platelet and neutrophil engraftment, number of days in the hospital and transfusion requirements are shown in Table 2 . Five patients did not require RBC transfusion, and platelet transfusion was not required in one patient. Two months after transplant, we could not find statistically significant differences between the number of WBC, ANC, platelets or hemoglobin before and after transplantation (data not shown). There was no correlation between the number of courses of chemotherapy, the use of previous radiotherapy and neither the WBC or platelet engraftment. However, there was a highly significant correlation between the number of CD34 + cells infused and both platelet (P = 0.008) and neutrophil (P = 0.002) engraftment.
Leukemia
Table 2
Engraftment, transfusion requirements and hospitalization after infusion of PBPC mobilized with cyclophosphamide, filgrastim and r-metHuSCF 
Toxicity
All patients were evaluable for safety. A comparison between the incidence of adverse events in our study and previous studies is shown in Table 3 . [10] [11] [12] 14, 17, 18 During the mobilization phase, seven patients (26%) developed neutropenic fever and required hospitalization for intravenous antibiotics. However, in none of these cases was PBPC harvest delayed beyond day +11. Development of neutropenic fever had no impact on the number of CD34 + cells obtained with two aphereses (differences between CD34 + cells obtained in patients who developed neutropenic fever and patients not developing neutropenic fever was not statistically significant) (data not shown).
Discussion
The most relevant findings of our study are first, that mobilization with chemotherapy, r-metHuSCF and filgrastim results in significantly large numbers of CD34 + cells collected with very mild toxicity and second, that under these conditions, the number of CD34 + cells infused is associated with time to platelet and neutrophil engraftment. Recent studies have suggested that the addition of r-metHuSCF to G-CSF for mobilization of PBPC significantly increases the number of PB CD34 + cells collected but nevertheless, does not reduce the morbidity and/or mortality associated with autologous SCT or shorten platelet or neutrophil engraftment. 9, 10, 14, 17 This benefit may be outweighed in some cases by the increase in sideeffects associated with administration of r-metHuSCF and related to the effect of r-metHuSCF on mast cell degranulation and release of histamine. In our study we selected a subset of patients that had received previous chemotherapy and were more likely to have difficulties in mobilizing PBPC for transplantation. 19, 20 By adding r-metHuSCF to cyclophosphamide and G-CSF we obtained a very large number of CD34 + cells in most patients with a single apheresis procedure and enough cells for transplantation in all cases.
The addition of SCF to G-CSF results in prolonged mobilizing effect thus increasing the number of days in which PBPC may be harvested. 9 Because delaying apheresis until the day the WBC was above 7.5 × 10 9 /l might result in a higher PBPC collection without a significant reduction in the percentage of CD34
+ cells, we decided to set that threshold for initiating apheresis. Although we did not perform any comparison, we + cell dose and engraftment has been clearly described. [21] [22] [23] Increasing the number of CD34 + cells above 5 × 10 6 per kilogram results in a more rapid engraftment. It is clear than the addition of r-metHuSCF increases the number of CD34
+ cells collected and that the infusion of more cells shortens the number of days to engraftment and reduces hospitalization, clearly suggesting the benefit of increasing the number of infused CD34 + cells. 10, 11, 14, 17, 18 A potential advantage of using r-metHuSCF relies on the type of hematopoietic cells that are mobilized. Studies performed in our group of patients and previously reported 16 demonstrated that besides mobilizing myeloid and erythroid progenitors, a significant number of CD16 + antigen-presenting cells are mobilized into the PB of our patients. Although rmetHuSCF contributes in vitro to the development of dendritic cells, the potential effect on mobilization of DC has not been clearly established. [24] [25] [26] The frequency and severity of some side-effects in the different studies has varied and in overall, studies in which no chemotherapy has been used for mobilization might have a lower incidence of adverse reactions. In our study the incidence of bone pain and erythema was lower than that which has been described in previous studies in which r-metHuSCF has been administered without chemotherapy. 14, 17 No severe alergic reactions were reported in our study.
In conclusion, treatment with chemotherapy, r-metHuSCF and filgrastim in patients with previously treated breast cancer results in mobilization of very large numbers of CD34 + cells with very mild toxicity related to administration of rmetHuSCF. The number of CD34 + cells infused after highdose chemotherapy correlates with time to platelet and neutrophil engraftment and number of hospitalization days thus reducing the morbidity of the procedure. Our results suggest a benefit of the addition of r-metHuSCF and may warrant a phase III confirmatory clinical trial.
